ID   SBcl2
AC   CVCL_D732
SY   SBCL2; SbCl2; Sbcl2; SB cell line, clone-2; SB clone 2; SB2; SBC2
DR   cancercelllines; CVCL_D732
DR   ChEMBL-Cells; CHEMBL4630603
DR   ChEMBL-Targets; CHEMBL4630702
DR   Cosmic; 686394
DR   Cosmic; 1507619
DR   Cosmic; 1665009
DR   Cosmic; 2647645
DR   GEO; GSM186455
DR   GEO; GSM186456
DR   Lonza; 831
DR   Progenetix; CVCL_D732
DR   PubChem_Cell_line; CVCL_D732
DR   Wikidata; Q54952190
RX   PubMed=2064308;
RX   PubMed=21424129;
RX   PubMed=21863025;
RX   PubMed=25645078;
RX   PubMed=28196595;
RX   PubMed=29492214;
WW   Info; MCLP; -; https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Unspecified (PubMed=29492214).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Homozygous (PubMed=25645078; PubMed=29492214).
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Misspelling: SBc12; Cosmic=686394; Cosmic=1507619.
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_D731 ! SBcl1
OI   CVCL_VW99 ! SBcl3
SX   Male
AG   46Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 10-04-25; Version: 22
//
RX   PubMed=2064308;
RA   Verschraegen C.F., Giovanella B.C., Mendoza J.T., Kozielski A.J.,
RA   Stehlin J.S. Jr.;
RT   "Specific organ metastases of human melanoma cells injected into the
RT   arterial circulation of nude mice.";
RL   Anticancer Res. 11:529-535(1991).
//
RX   PubMed=21424129; DOI=10.3892/or.2011.1220;
RA   Manca A., Sini M.C., Izzo F., Ascierto P.A., Tatangelo F., Botti G.,
RA   Gentilcore G., Capone M., Mozzillo N., Rozzo C., Cossu A., Tanda F.,
RA   Palmieri G.;
RT   "Induction of arginosuccinate synthetase (ASS) expression affects the
RT   antiproliferative activity of arginine deiminase (ADI) in melanoma
RT   cells.";
RL   Oncol. Rep. 25:1495-1502(2011).
//
RX   PubMed=21863025; DOI=10.1038/bjc.2011.324; PMCID=PMC3185940;
RA   De Luca A., Lamura L., Strizzi L., Roma C., D'Antonio A.,
RA   Margaryan N.V., Pirozzi G., Hsu M.-Y., Botti G., Mari E., Hendrix M.J.C.,
RA   Salomon D.S., Normanno N.;
RT   "Expression and functional role of CRIPTO-1 in cutaneous melanoma.";
RL   Br. J. Cancer 105:1030-1038(2011).
//
RX   PubMed=25645078; DOI=10.1186/s12943-015-0293-5; PMCID=PMC4320814;
RA   Atefi M., Titz B., Avramis E., Ng C., Wong D.J.L., Lassen A.,
RA   Cerniglia M., Escuin-Ordinas H., Foulad D., Comin-Anduix B.,
RA   Graeber T.G., Ribas A.;
RT   "Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.";
RL   Mol. Cancer 14:27.1-27.12(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29492214; DOI=10.18632/oncotarget.23989; PMCID=PMC5823576;
RA   Sini M.C., Doneddu V., Paliogiannis P., Casula M., Colombino M.,
RA   Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G.;
RT   "Genetic alterations in main candidate genes during melanoma
RT   progression.";
RL   Oncotarget 9:8531-8541(2018).
//